NCT00923884 is a clinical trial in Carcinoma, Non-Small Cell Lung, sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT00923884?

NCT00923884 is sponsored by National Cancer Institute (NCI).

What condition does NCT00923884 study?

NCT00923884 studies Carcinoma, Non-Small Cell Lung, Carcinoma, Small-Cell Lung.

Is NCT00923884 still recruiting?

NCT00923884 is currently completed. Last updated 9 October 2019.

Last reviewed 2019-10-09 · How we verify

NCT00923884

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

Completed Last updated 9 October 2019

What this trial tests

trial in Carcinoma, Non-Small Cell Lung in 546 participants. Completed in 20 April 2018.

Timeline

18 March 2009

20 April 2018

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	546
Start date	18 March 2009
Estimated completion	20 April 2018
Sites	1 location across United States

Conditions studied

Carcinoma, Non-Small Cell Lung — all drugs for Carcinoma, Non-Small Cell Lung →
Carcinoma, Small-Cell Lung — all drugs for Carcinoma, Small-Cell Lung →

Sponsor

National Cancer Institute (NCI)

Who can join

Adults 18 to 100, any sex, with Carcinoma, Non-Small Cell Lung or Carcinoma, Small-Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: * The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer. Objectives: * To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer. * To establish a repository of genetic information for future studies of these differences and their relation to lung cancer. Eligibility: * Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute. Design: * After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential. * Approximately half a tablespoon of blood will be drawn. * Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study * Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Carcinoma, Non-Small Cell Lung

Currently open trials in the same condition.

NCT07227298 — Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer · Phase 1, PHASE2 · recruiting
NCT06868277 — A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic · Phase 3 · recruiting
NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
NCT04389632 — A Study of Sigvotatug Vedotin in Advanced Solid Tumors · Phase 1 · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00923884 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 9 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00923884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing